Opinion Piece from Pharmacists United for Truth & Transparency ( " PUTT " )
Pharmacists United for Truth& Transparency ( " PUTT " ) is a non-profit advocacy organization founded by independent pharmacists and pharmacy owners devoted to exposing what they describe as anti-competitive tactics deployed by the largest Pharmacy Benefit Managers (PBMs - aka Pharmacy Benefit Companies or PBCs as the trade organization known as the Pharmaceutical Care Management Association or PCMA has tried to rebrand its industry since the acronym PBM has become toxic) recently published an opinion piece with an interesting title: " The Deadliest Addiction in the U.S. Isn ' t What You Think It Is " (read it athttps:...
Source: Scott's Web Log - July 12, 2023 Category: Endocrinology Tags: 2023 drug prices PBM Pharmacists United for Truth & Transparency PUTT Source Type: blogs
African American men respond better to treatments for advanced prostate cancer in clinical trials
Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease.
But new research also shows that African American men who receive the most advanced treatments for late-stage prostate cancer can live at least as long — or even longer — than their Caucasian counterparts.
Why is this the case? Scientists are searching for an explanation. “The fact that African American men have better survival is of huge research interest,” said Dr. Stephen Freedlan...
Source: Harvard Health Blog - March 26, 2019 Category: Consumer Health News Authors: Charlie Schmidt Tags: Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
Zytiga Lowers PSA in men with high-risk prostate cancer, at a cost in side-effects
Prostate cancer survivors during the era 2005-2013, as you'll see from our tag cloud (sidebar), were bombarded by Dendreon's controversial campaign to speed FDA approval of its immunotherapy vaccine Provenge. Since then, Provenge hype has calmed down, while the push for Abiraterone acetate (Zytiga) has heated up. Abiraterone (generic name) aka Zytiga (brand name) is ...continue reading Zytiga Lowers PSA in men with high-risk prostate cancer, at a cost in side-effects (Source: psa-rising.com/blog)
Source: psa-rising.com/blog - May 24, 2015 Category: Cancer & Oncology Authors: Jacquie Strax Tags: Abiraterone CRPC Prostate Cancer Side Effects Zytiga Source Type: blogs
J&J buy Aragon
Johnson & Johnson, the world’s biggest maker of health-care products, agreed to buy Aragon Pharmaceuticals Inc. and its experimental prostate cancer drug in a deal worth as much as $1 billion.
Aragon will receive an initial cash payment of $650 million, New Brunswick, New Jersey-based J&J said in a statement today. Additional payments of as much as $350 million may follow if Aragon’s cancer candidate, ARN-509, achieves certain milestones, J&J said.
Aragon’s main experimental prostate cancer drug is in the second of three stages usually required for regulatory approvals in the U.S. and may complement...
Source: PharmaGossip - June 17, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Alex Gorsky And The Battered J&J Credo
Last week was significant for Johnson & Johnson ceo Alex Gorsky in different ways. For one, it was the first time that he presided over a discussion of an annual earnings report as ceo of the healthcare giant. At the same time, J&J made headlines, once again, over a potentially scandalous disclosure of previously unknown data concerning its troubed hip implants.
So it was a good-news-bad-news few days. On one hand, Gorsky had a chance to engage investors and analysts as he outlined his views on remaking the troubled consumer healthcare business, shifting the product portfolio and the resurgent pharmaceutical unit...
Source: Pharmalot - January 28, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Alex Gorsky Bill Weldon FDA JJ Johnson & Johnson Motrin Tylenol Source Type: blogs
Pharmalot… Pharmalittle… Good Morning
Good morning, everyone, and how are you today? We hope the weekend was relaxing and invigorating, because now, the familiar routine of deadlines and meetings and all manner of busywork has returned. What can you do? So, to cope, we are brewing that needed cup of stimulation. Feel free to join us. After all, a pick-me-up is not a bad thing. Meanwhile, here are some tidbits to get you going. Hope your day goes well and you conquer the world…
California Legislator Vows To Curb Reckless Prescribing (Los Angeles Times)
Patients Are Rarely Told About Medication Errors: Study (Reuters)
Job Cuts Feared At AstraZeneca R&...
Source: Pharmalot - January 14, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Abbott Laboratories Abbvie AstraZeneca Contraceptives Diovan EMA Flu JJ Johnson & Johnson Layoffs Medication Errors Mesh Implants Novartis OTC Drugs Over-the-Counter Drugs Patents Prescription Painkillers Source Type: blogs
